About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
European Journal of Nuclear Medicine and Molecular Imaging
›
Top Articles
European Journal of Nuclear Medicine and Molecular Imaging
Nuclear Medicine
(top 60%)
Impact Factor
(top 60%)
extended IF
89
(top 4%)
H-Index
426
authors
3.4K
papers
58K
citations
4K
citing journals
13.2K
citing authors
Most Cited Articles of European Journal of Nuclear Medicine and Molecular Imaging
Title
Year
Citations
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
1993
1.3K
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
2001
487
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients
1996
418
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients
2001
392
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
1996
386
Nitroimidazoles and imaging hypoxia
1995
317
Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment
2000
241
Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus
1991
238
Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours
1996
237
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000
2001
230
FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy
2000
229
Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck
1999
222
Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate
1986
202
18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels
2001
198
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism
2001
198
First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent
1993
198
Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography
1994
193
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures
2001
190
Advantage of delayed whole-body FDG-PET imaging for tumour detection
2001
189
Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer
1997
185
Recent progress in fluorine-18 labelled peptide radiopharmaceuticals
2001
180
Imaging of dopamine transporters in humans with technetium-99m TRODAT-1
1996
180
Experience with carbon-11 choline positron emission tomography in prostate carcinoma
2000
177
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives
2001
171
Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases
1997
168
previous
1996
1997
1998
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.